Back to top
more

Rydex Series Trust Biotechnology Fund Investor Class: (MF: RYOIX)

(NASDAQ Mutual Funds) As of May 5, 2025 08:00 PM ET

$63.46 USD

-0.54 (-0.84%)

Zacks MF Rank

This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

4-Sell of 5       4  

View All Zacks Mutual Fund Rank #1's

Latest Performance as of Mar 31, 2025

Total Return %* Percentile Rank Objective
YTD -1.34 63
3 months -1.34 63
6 months -9.28 46
1 Year -2.85 36
3 Year 0.07 70
5 Year 5.62 85
10 Year 2.45 87

* Annual for three years and beyond.

Zacks Premium Research for RYOIX

Zacks MF Rank

This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

Sell 4
MF Report

Mutual Funds Research & Tools

Search Similar Mutual Funds

Research similar Mutual Funds with higher ranks and performance ratings.

Mutual Funds Comparison View (minimum of 2)

Mutual Funds Screener

Narrow down the universe of 18,000+ funds we rank with our robust, yet easy-to-use mutual fund screeners. Select from up to 50 different data points to find the mutual funds that best Screen meet your unique criteria.

Portfolio Statistics

% Unrealized Gain 45.22
% Yield 0.00
% SEC Yield NA
Net Assets (Mil $) 3/31/2025 70.09
% Turnover 3/31/2025 102.00

Risk

3 Year 5 Year 10 Year
Beta 0.75 0.79 0.94
Alpha -6.94 -7.84 -7.41
R Squared 0.56 0.53 0.46
Std. Dev. 17.08 18.47 21.48
Sharpe -0.16 0.25 3.00

Sector / Country Weightings

As of 3/31/2025 % of Portfolio
Health 65.22
Other 14.70
Services 13.16
Non-Durable 2.78
Industrial Cyclical 2.14
Technology 2.00

Portfolio Holdings

Top Equity Holdings
(As of 12/31/2024)
% of Portfolio Value (Mil$)
ABBVIE INC 8.16 7.47
AMGEN INC 5.27 4.82
GILEAD SCIENCES INC 4.87 4.46
VERTEX PHARMACEUTICALS IN 4.36 3.99
REGENERON PHARMACEUTICALS 3.92 3.59
CORTEVA INC 2.78 2.54
ALNYLAM PHARMACEUTICALS I 2.42 2.21
ASTRAZENECA PLC ADR 2.25 2.06
BIOGEN INC 2.14 1.96

Stock Holding % of Net Assets

As Of 12/31/2024
Total Issues 75
Avg. P/E 38.51
Avg. P/Book 4.93
Avg. EPS Growth 15.5
Avg. Market Value (Mil $) 60,142

Composition

% of Portfolio
Stocks 99.98
Foreign Stocks 5.93
Cash 1.34
Bonds 0.00
Foreign Bonds 0.00
Preferred 0.00
Convertible 0.00
Other -1.32
Foreign Hedged 0.00

Style Analysis

% of Portfolio
Large Growth 0.00
Large Value 0.00
Small Growth 20.28
Small Value 0.00
Foreign Stock 13.56
Emerging Market 0.00
Precious Metal 2.17
Intermediate Bond 16.87
Foreign Bond 0.00
High Yield Bond 0.00